NVIDIA launches Jetson Thor robotics computers for physical AI systems
In a recent transaction filed with the Securities and Exchange Commission, Carlos Luis Lopez, the Senior Vice President and General Counsel of ChromaDex Corp. (NASDAQ:CDXC), acquired 273 shares of common stock. The purchase, which took place on March 7, 2025, was made at a price of $7.86 per share, amounting to a total value of $2,145. The timing of this insider purchase coincides with the stock’s impressive performance, showing a 40% gain in the past week and a remarkable 347% return over the last year, according to InvestingPro data.
Following this transaction, Lopez’s direct ownership in the company increased to 2,251 shares. ChromaDex Corp. is a Los Angeles-based company that specializes in medicinal chemicals and botanical products. The company maintains a strong financial position with a current ratio of 3.57 and operates with moderate debt levels. InvestingPro analysis reveals 15+ additional key insights about CDXC’s valuation and growth prospects, available in the comprehensive Pro Research Report.
In other recent news, ChromaDex Corporation reported impressive financial results for the fourth quarter of 2024, significantly exceeding market expectations. The company posted an earnings per share (EPS) of $0.09, surpassing the projected $0.02, and achieved revenue of $29.1 million, which was higher than the anticipated $26.78 million. This strong performance is attributed to product innovation and operational efficiency. ChromaDex also reported a full-year net income of $8.6 million and ended the year with $44.7 million in cash and no debt, highlighting its financial strength.
Looking ahead, ChromaDex projects an 18% revenue growth for 2025, with modest improvements in gross margins. The company plans to continue investing in research and development, focusing on new product formulations and pharmaceutical applications. Additionally, a corporate rebranding is anticipated, along with a potential spin-off for drug development. During the earnings call, analysts inquired about the company’s plans for Parkinson’s disease treatment and challenges related to NAD testing, which the executives addressed. These developments reflect ChromaDex’s strategic focus on innovation and market expansion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.